Overview

A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
To demonstrate that tiotropium (Spiriva®) does not prolong the QT interval of the ECG more than placebo
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Tiotropium Bromide